The patent issued by the United States Patent and Trademark Office (USPTO) under the name of "Methods for Stabilizing Retinoids, Retinoid Containing Composition, and Methods of Using a Retinoid Containing Composition," will last till 14 April 2029.
The patent further substantiates Invisicare benefits and also covers retinoid stabilization method and a retinoid composition.
Skinvisible Pharmaceuticals president and CEO Terry Howlett said the patent increases the depth of intellectual property protection for acne formulations.
"This patent provides potential licensees with a further layer of exclusivity and will assist Skinvisible as it actively seeks partnering, licensing and co-development arrangements globally to maximize the potential of this recently issued patent," Howlett added.